Edition:
India

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,374JPY
28 Jun 2017
Change (% chg)

¥-6 (-0.43%)
Prev Close
¥1,380
Open
¥1,376
Day's High
¥1,384
Day's Low
¥1,370
Volume
9,011,300
Avg. Vol
8,157,271
52-wk High
¥1,779
52-wk Low
¥1,338

4503.T

Chart for 4503.T

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Overall

Beta: 0.55
Market Cap(Mil.): ¥2,854,976.00
Shares Outstanding(Mil.): 2,068.82
Dividend: 18.00
Yield (%): 2.46

Financials

  4503.T Industry Sector
P/E (TTM): 13.34 13.64 17.41
EPS (TTM): 103.44 -- --
ROI: 15.58 -6.98 -5.24
ROE: 17.28 -6.46 -4.49

BRIEF-Astellas, Pfizer announce amendment to clinical research protocol for phase 3 prosper trial of enzalutamide

* Astellas and Pfizer announce amendment to clinical research protocol for phase 3 prosper trial of enzalutamide in patients with non-metastatic castration-resistant prostate cancer

09 Jun 2017

BRIEF-Seattle Genetics, Astellas announce updated enfortumab vedotin phase 1 data in metastatic urothelial cancer ​

* Trial evaluating enfortumab vedotin in combination with CPIs is also planned for later in the year​

05 Jun 2017

BRIEF- Astellas Pharma completes acquisition of Ogeda SA in Belgium

* Says it has completed the acquisition of Ogeda SA, a drug discovery company located in Gosselies, Belgium, and Ogeda has become a wholly owned subsidiary of the company as of CET May 17

17 May 2017

BRIEF- Astellas Pharma to discontinue ASP8273 treatment and close randomization for clinical study protocol 8273-CL-0302

* Says it announced the discontinuation of ASP8273 treatment arm in the the late-stage SOLAR trial evaluating the efficacy and safety of ASP8273 versus erlotinib/gefitinib

11 May 2017

BRIEF-Astellas Pharma says transfer of 16 Long-Listed Products in Japan to LTL Pharma

* Says Astellas and LTL Pharma Co., Ltd.confirmed the relevant closing conditions are met on April 28 to allow the transfer of the assets related to Astellas’ 16 long-listed products in Japan to LTL Pharma

28 Apr 2017

BRIEF-Astellas Pharma to retire treasury shares

* Says it will retire 85 million shares( 4 percent of outstanding ) of its common stock on May 31

27 Apr 2017

BRIEF-Astellas Pharma to acquire Ogeda SA

* under agreement, Astellas has agreed to pay up to a total of eur 800 million

03 Apr 2017

BRIEF-RIBOMIC plans joint research agreement with Astellas pharma

* Says it plans to enter into joint research agreement with Astellas pharma Inc, regarding R&D of aptamers pharmaceuticals

21 Mar 2017

BRIEF-X-Chem signs broad drug discovery collaboration with Astellas Pharma

* X-Chem Inc - announced signing of a broad drug discovery collaboration with Astellas Pharma Inc

20 Mar 2017

More From Around the Web

Earnings vs. Estimates